Total Funding
32
42
Total FundingSeed raised
Growth Score
-6 pts
Heat Score
-21 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
159180
Sisu Pharma is developing drugs against a new target to treat prostate cancer.
Jiaoti Huang: Co-Founder- Sean O'Brien: CEO and Co-Founder
About the Company
Sisu Pharma is dedicated to developing targeted drugs for patients with therapy-resistant Prostate Cancer. Prostate Cancer is the second most common cancer in men worldwide and there were over 1.3 million new cases of the disease globally in 2018. There are several treatments available for Prostate Cancer but none are curative and prolonged
treatment inevitably results in resistance and death. Sisu Pharma’s proprietary technology specifically targets a key protein that is critical to the survival and spread of advanced Prostate Cancer, providing desperately needed treatment for patients with no remaining options.
